Headache

Papers
(The H4-Index of Headache is 27. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Migraine treatment in pregnancy: A survey of comfort and treatment practices of women's healthcare providers205
Virtual issue: Education in headache medicine: Insights and advancements from 2023 to 202491
Identifying cognitive‐affective mechanisms underlying disability in episodic migraine: Using the fear avoidance model to examine interactions77
Evidence for increased background neural noise in migraine with aura: Hyperactive but not hyperresponsive73
Assessing the influence of migraine on ischemic penumbra and on the prognosis of ischemic stroke: A prospective cohort study55
Erratum51
Drug‐resistant epicrania fugax: Responding to onabotulinumtoxinA50
Temporary occipital nerve stimulation as transitional therapy for chronic intractable cluster headache: A case report and proof of concept49
Response to Letter to the Editor regarding “Calcitonin gene‐related peptide and headache: Comparison of two commonly used assay kits highlights the perils of measuring neuropeptides with enzyme‐linked48
Migraine screening in English and Spanish46
Cortical synchronization of spontaneous trigeminal neuropathic pain monitored with in vivo optical imaging of calcium activity in freely moving mice43
Anxiety, depression, and headache‐related disability in a large pediatric clinic–based sample42
A retrospective analysis of the use of candesartan for migraine prevention in adolescents40
Characteristics associated with response to subcutaneously administered anti‐CGRP monoclonal antibody medications in a real‐world community cohort of persons living with migraine: A retrospective clin35
The impacts of migraine on functioning: Results from two qualitative studies of people living with migraine34
Persistence, effectiveness, and tolerability of anti‐calcitonin gene–related peptide monoclonal antibodies in patients with chronic migraine32
Effectiveness and acceptability of oral migraine preventives: A prospective, observational study32
Menopausal hormone therapy, migraine history, and headache severity: Results from the Women's Health Initiative Hormone Therapy clinical trials32
A 51‐year‐old female presenting with headache and vision loss32
Facial variant of epicrania fugax secondary to a cerebellopontine angle meningioma32
Genetic migraine disorders and the response to calcitonin gene‐related peptide antagonist treatment31
Normal glymphatic system function in patients with new daily persistent headache using diffusion tensor image analysis along the perivascular space31
Pituitary adenylate cyclase–activating polypeptide blockade in migraine and the transformation of clinical practice30
A 52‐week open‐label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine30
Headache in mitochondrial diseases: From migraine to stroke‐like episodes30
Pilot study evaluating treatment with sumatriptan for moderate to severe post‐traumatic headache: A phase 2 open‐label study29
Routine migraine screening as a standard of care for Women's health: A position statement from the American Headache Society27
Zavegepant and lactation: What the pharmacokinetic data suggests27
Long‐term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis27
Headache and psychological variables as predictors of disability in individuals with primary headache disorders27
0.13738203048706